EUVIMEDEUVIMED entdecken
Crossref

Testing insulin‐like growth factor messenger RNA–binding protein 3 as a surrogate immunohistochemical marker for indeterminate thyroid nodules with THADA fusion in both cytologic and surgical specimens

Di Ai iD, Youjie Zhang, Kartik Viswanathan, Jilun Zhang, Kelly R Magliocca, Scott Steward-Tharp, Wen-Yu Hsiao iD, Qiuying Shi iD

Cancer Cytopathology · 2026

DOI: 10.1002/cncy.70076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Cytopathology, 2026. Verfasst von Di Ai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: RNA-Binding Proteins, Thyroid Nodule, Biomarkers, Tumor, Thyroid Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Thyroid adenoma‐associated ( THADA ) gene fusions are recurrent alterations in thyroid nodules that lead to the overexpression of insulin‐like growth factor messenger RNA–binding protein 3 (IMP3). Although IMP3 immunohistochemistry has been studied in thyroid tumors, its utility for detecting THADA fusion–positive thyroid specimens remain unassessed.

Methods

The authors evaluated IMP3 expression in cytologic and surgical specimens from 20 indeterminate thyroid nodules. Eleven cases harbored THADA fusions, including THADA::IGF2BP3 ( n = 9) and THADA::TRA2A ( n = 2), whereas nine control cases lacked detectable THADA fusions. Hematoxylin‐and‐eosin staining and immunohistochemistry for IMP3 and NRAS Q61R were performed on available cell blocks and surgical specimens. Staining was scored based on extent and intensity, with a composite score >2 considered positive.

Results

All nodules with THADA fusions exhibited strong, diffuse, cytoplasmic IMP3 staining in lesional follicular cells, with no staining in adjacent normal thyroid tissue. All control cases were negative for IMP3. NRAS Q61R immunostaining was negative across all cases.

Conclusions

The current findings in a limited cohort demonstrate that IMP3 is a promising surrogate marker for indeterminate thyroid nodules with THADA fusions in both cytologic and surgical specimens. In addition, IMP3 staining may aid in detecting subtle capsular or vascular invasion.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA-Binding ProteinsThyroid NoduleBiomarkers, TumorThyroid NeoplasmsOncogene Proteins, FusionHumansImmunohistochemistryFemaleMaleMiddle AgedAdultBiopsy, Fine-NeedleRibonucleoproteins, Small Nucleolar

Stichwörter der Autor:innen

THADA fusionThyroSeqcytologyimmunohistochemistryinsulin‐like growth factor messenger RNA–binding protein 3 (IMP3)thyroid nodule

Substanzen

RNA-Binding ProteinsBiomarkers, TumorIMP3 protein, humanIGF2BP3 protein, humanOncogene Proteins, FusionRibonucleoproteins, Small Nucleolar

Autor:innen und Institutionen

  • Division of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
  • Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, Georgia, USA.
  • School of Medicine, University of Massachusetts, Boston, Massachusetts, USA.
  • Department of Pathology and Laboratory Medicine, School of Medicine, Oregon Health Science University, Portland, Oregon, USA.

ORCID-Profile: Di Ai, Wen-Yu Hsiao, Qiuying Shi

Zitieren

APA

Ai, D., Zhang, Y., Viswanathan, K., Zhang, J., Magliocca, K. R., Steward-Tharp, S., Hsiao, W. Y., & Shi, Q. (2026). Testing insulin‐like growth factor messenger RNA–binding protein 3 as a surrogate immunohistochemical marker for indeterminate thyroid nodules with THADA fusion in both cytologic and surgical specimens. Cancer Cytopathology. https://doi.org/10.1002/cncy.70076

Vancouver

Ai D, Zhang Y, Viswanathan K, Zhang J, Magliocca KR, Steward-Tharp S, et al. Testing insulin‐like growth factor messenger RNA–binding protein 3 as a surrogate immunohistochemical marker for indeterminate thyroid nodules with THADA fusion in both cytologic and surgical specimens. Cancer Cytopathology. 2026. doi:10.1002/cncy.70076

BibTeX
@article{Ai2026,
  author = {Ai, Di and Zhang, Youjie and Viswanathan, Kartik and Zhang, Jilun and Magliocca, Kelly R and Steward-Tharp, Scott and Hsiao, Wen-Yu and Shi, Qiuying},
  title = {Testing insulin‐like growth factor messenger RNA–binding protein 3 as a surrogate immunohistochemical marker for indeterminate thyroid nodules with THADA fusion in both cytologic and surgical specimens},
  journal = {Cancer Cytopathology},
  year = {2026},
  doi = {10.1002/cncy.70076}
}
Kostenlos starten →